PT  - JOURNAL ARTICLE
AU  - Virginia Norris
AU  - Jane Bentley
AU  - Sandra Kent
AU  - Dave Singh
AU  - Malcolm Boyce
AU  - Brian Leaker
TI  - The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen
DP  - 2011 Sep 01
TA  - European Respiratory Journal
PG  - p3966
VI  - 38
IP  - Suppl 55
4099  - http://erj.ersjournals.com/content/38/Suppl_55/p3966.short
4100  - http://erj.ersjournals.com/content/38/Suppl_55/p3966.full
SO  - Eur Respir J2011 Sep 01; 38
AB  - Background: GSK2190915 is a potent 5-lipoxygenase activating protein inhibitor, thereby inhibiting the synthesis of leukotrienes and 5-oxo-ETE.Objective: To assess the effects of GSK2190915 on the allergen induced early asthmatic response (EAR).Methods: 19 patients with mild asthma were enrolled in this 3-centre, double- blind, 3-way crossover study. They took 10 and 50 mg GSK2190915 and placebo orally, once daily for 3 days, in randomised order. On Day 3 they had an inhaled allergen challenge.Results: GSK2190915 had a significant effect on the EAR, the treatment difference from placebo for 10 mg was 0.212 L (0.044, 0.379) and for 50 mg was 0.409 L (0.242, 0.576) for minimum FEV1 in the 2 hours after allergen inhalation. The magnitude of the effect with 50 mg GSK2190915 in this study was comparable to that observed with 100 mg on the EAR in a separate study [1]. Safety and tolerability were good.View this table:Conclusion: GSK2190915 has shown a significant, dose related, inhibition of the EAR to inhaled allergen.References:1. V Norris et al. ERS conference 2011.ClinicalTrials.gov identifier NCT00812773